Related Experiment Video

Updated: Jun 21, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

D-amphetamine toxicity in freshly isolated rat hepatocytes: a possible role of CYP3A

Vessela Vitcheva1, Magdalena Kondeva-Burdina, Mitka Mitcheva

  • 1Laboratory of Drug Metabolism and Drug Toxicity, Department of Pharmacology, Pharmacotherapy, and Toxicology, Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria. vesselavitcheva@yahoo.com

Arhiv Za Higijenu Rada I Toksikologiju
|July 8, 2009
PubMed

Insights

This study investigated D-amphetamine toxicity in rat liver cells, finding that CYP3A enzymes play a key role in its harmful effects. Nifedipine treatment increased D-amphetamine

Area of Science:

  • Hepatology
  • Toxicology
  • Pharmacology

Background:

  • D-amphetamine is a stimulant with known toxic effects.
  • Cytochrome P450 3A (CYP3A) enzymes are crucial for drug metabolism and can influence toxicity.
  • Understanding the specific mechanisms of D-amphetamine hepatotoxicity is important for clinical safety.

Purpose of the Study:

  • To investigate the toxicity of D-amphetamine in isolated rat hepatocytes.
  • To determine the potential involvement of CYP3A in D-amphetamine-induced liver injury.
  • To assess how CYP3A induction affects D-amphetamine cytotoxicity.

Main Methods:

  • Isolated rat hepatocytes were used to study D-amphetamine toxicity.
  • Hepatocytes from rats pre-treated with nifedipine (a CYP3A inducer) were exposed to D-amphetamine.
  • Cell viability, lactate dehydrogenase (LDH) release, and glutathione (GSH) levels were measured.
  • Amiodarone (a CYP3A inhibitor) was used to confirm the role of CYP3A.

Main Results:

  • D-amphetamine significantly reduced cell viability and glutathione levels while increasing LDH release in isolated hepatocytes.
  • Pre-treatment with nifedipine potentiated D-amphetamine's toxic effects, indicating increased hepatotoxicity.
  • Inhibition of CYP3A with amiodarone significantly reduced the potentiation of D-amphetamine cytotoxicity caused by nifedipine.

Conclusions:

  • D-amphetamine exhibits significant toxicity in isolated rat hepatocytes.
  • The cytochrome P450 3A enzyme system is involved in the metabolism and subsequent hepatotoxicity of D-amphetamine.
  • CYP3A induction can exacerbate D-amphetamine-induced liver injury.

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Isolation of Primary Rat Hepatocytes with Multiparameter Perfusion Control07:35

Isolation of Primary Rat Hepatocytes with Multiparameter Perfusion Control

Published on: April 5, 2021

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...